Sidera Bio ApS: Financial statements 2025
CVR: 44381699
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Sidera Bio ApS (CVR 44381699) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR -5,287,281 and a net result of EUR -6,924,629. Equity in the 2025 report amounted to EUR 85,864,083. The solvency ratio was 96.6%. The company had 4 employees in the financial year.
- Gross Profit
- EUR -5,287,281
- Profit/Loss
- EUR -6,924,629
- Equity
- EUR 85,864,083
- Total Assets
- EUR 88,858,903
- Employees
- 4
Official annual report
How creditworthy is Sidera Bio ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of November 18, 2025, Søren Møller has joined the board of directors of Sidera Bio ApS.
As of November 18, 2025, Stefan Emanuel Luzi has joined the board of directors of Sidera Bio ApS.
As of November 18, 2025, Nandita Shangari has joined the board of directors of Sidera Bio ApS.
As of November 18, 2025, Tim Lohoff has joined the board of directors of Sidera Bio ApS.
As of November 18, 2025, Novo Holdings A/S is registered as an owner of Sidera Bio ApS with an ownership share of 15%.
As of November 18, 2025, is registered as an owner of Sidera Bio ApS with an ownership share of 15%.
As of November 18, 2025, is registered as an owner of Sidera Bio ApS with an ownership share of 25%.
As of November 18, 2025, is registered as an owner of Sidera Bio ApS with an ownership share of 5%.
As of November 18, 2025, is registered as an owner of Sidera Bio ApS with an ownership share of 10%.
Sidera Bio ApS has published its interim report for the period October 19, 2023 – December 31, 2024.
About Sidera Bio ApS
Sidera Bio ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named GhostBio ApS. The management consists of Keld Flintholm Jørgensen. The board consists of Peter Høngård Andersen (chair), Mads Peter Hemmingsen, Nandita Shangari and Stefan Emanuel Luzi. The company's owners include Novo Holdings A/S, RA Capital Healthcare Fund, L.P. and Forbion Ventures Fund VI Coöperatief U.A.. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported a gross profit of EUR -5,287,281 and a net result of EUR -6,924,629. Equity in the 2025 report amounted to EUR 85,864,083.